Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.4B 8.13B 7.59B 6.97B 13.1B 895B 13.31B 89.08B 34.96B 448B 35.3B 34.52B 1,482B P/E 2026 *
-15.8x
P/E 2027 * -30.6x
Enterprise Value 9B 7.79B 7.27B 6.67B 12.55B 857B 12.75B 85.33B 33.49B 430B 33.81B 33.07B 1,420B EV / Sales 2026 *
9.78x
EV / Sales 2027 * 6.53x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -
1 day+3.80%
1 week+9.25%
Current month+9.25%
1 month-34.48%
3 months-25.60%
6 months-34.61%
Current year-28.50%
1 week 52.16
Extreme 52.165
56.6
1 month 50
Extreme 50.005
70.35
Current year 50
Extreme 50.005
86.74
1 year 40.37
Extreme 40.37
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 01/07/2012
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/05/2000
Director TitleAgeSince
Director/Board Member 64 13/12/2005
Director/Board Member 73 01/05/2002
Director/Board Member 64 25/03/2019
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Buy

Director

5,000 0.0030%
15/07/26 Free

Director

3,399 0.0021%
15/07/26 Free

Director

3,399 0.0021%
Change 5-day change 1-year change 3-year change Capi.($)
+3.80%+9.25%+37.78%+44.58% 9.4B
+0.99%+1.78%+4.07%+16.73% 49.47B
+3.71%+9.40%+486.98%+592.14% 43.61B
+2.70%+1.57%+33.39%+8.85% 39.29B
+5.60%+10.21%+16.76%+85.72% 39.6B
+2.21%+6.75%+21.31%+53.37% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+37.75%+126.84% 16.49B
-0.11%+2.41%+6.24%+18.87% 14.01B
+0.75%+15.04%+78.59%+30.30% 12.77B
Average +2.28%+6.61%+80.32%+108.60% 27.39B
Weighted average by Cap. +2.58%+6.20%+101.82%+137.27%

Financials

2026 *2027 *
Net sales 921M 796M 744M 682M 1.28B 87.63B 1.3B 8.73B 3.43B 43.92B 3.46B 3.38B 145B 1.4B 1.21B 1.13B 1.04B 1.95B 133B 1.98B 13.28B 5.21B 66.86B 5.26B 5.15B 221B
Net income -590M -510M -477M -437M -822M -56.15B -835M -5.59B -2.19B -28.14B -2.22B -2.17B -93.04B -319M -276M -257M -236M -444M -30.34B -451M -3.02B -1.19B -15.2B -1.2B -1.17B -50.27B
Net Debt -396M -342M -320M -293M -551M -37.65B -560M -3.75B -1.47B -18.87B -1.49B -1.45B -62.38B -241M -208M -194M -178M -335M -22.91B -341M -2.28B -895M -11.48B -904M -884M -37.95B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,480
Date Price Change Volume
07/08/26 $56.56 +3.80% 2,009,230
06/08/26 $54.49 +0.55% 2,592,317
05/08/26 $54.19 -1.60% 2,122,267
04/08/26 $55.07 +1.06% 2,688,216
03/08/26 $54.49 +5.25% 3,212,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
56.56USD
Average target price
89.33USD
Spread / Average Target
+57.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock